Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
Ronald de WitJohann S de BonoCora N SternbergKarim FizaziBertrand TombalChristian WülfingGero KramerJean-Christophe EymardAristotelis BamiasJoan CarlesRoberto IacovelliBohuslav MelicharÁsgerður SverrisdóttirChristine TheodoreSusan FeyerabendCarole HelisseyAyse OzatilganChristine Geffriaud-RicouardDaniel Castellanonull nullPublished in: The New England journal of medicine (2019)
Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (Funded by Sanofi; CARD ClinicalTrials.gov number, NCT02485691.).